Drugs / Nemolizumab
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Nemluvio | — | 2025-02-12 | europa.eu ↗ |
Trials 23 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05405985 | Aug → Nov 2022 | — | Galderma R&D | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT07704775 | Sep 2026 → Sep 2027 expected | vulvar lichen sclerosus | University of Texas Southwestern Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07660835 | Jun 2026 → Jul 2028 expected | atopic eczema | Galderma R&D | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07047690 | Feb 2026 → May 2028 expected | systemic sclerosis | Galderma R&D | Recruiting | No outcome recorded |
| Phase 2 | NCT07074977 | Oct 2025 → Sep 2026 expected | — | Galderma R&D | Recruiting | No outcome recorded |
| Phase 2 | NCT05214794 | Apr 2022 → Jun 2024 | systemic sclerosis | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04921345 | Jun 2021 → Apr 2025 | atopic eczema | Galderma R&D | Completed | No outcome recorded |
| Phase 2 | NCT04365387 | Mar 2020 → Jul 2023 | atopic eczema | Galderma R&D | Completed | No outcome recorded |
| Phase 2 | NCT03921411 | Apr 2019 → Aug 2020 | atopic eczema | Galderma R&D | Completed | No outcome recorded |
| Phase 2 | NCT03181503 | Oct 2017 → Sep 2018 | prurigo nodularis | Galderma R&D | Completed | No outcome recorded |
| Phase 2 | NCT03100344 | Jun 2017 → Jul 2018 | atopic eczema | Galderma R&D | Completed | No outcome recorded |
| Phase 2 | NCT01986933 | Nov 2013 → Apr 2015 | atopic eczema | Chugai Pharmaceutical | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05075408 | Mar 2022 → Jan 2024 | — | Galderma R&D | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT05056779 | Jan → Jul 2023 | atopic eczema | Galderma R&D | Withdrawn | No outcome recorded |
| Phase 3 | NCT05052983 | Jan 2022 → Sep 2023 | prurigo nodularis | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT04204616 | Jan 2021 → Oct 2026 expected | prurigo nodularis | Galderma R&D | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04501666 | Sep 2020 → Nov 2022 | prurigo nodularis | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT04501679 | Aug 2020 → Mar 2022 | prurigo nodularis | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT03989206 | Dec 2019 → Aug 2026 overdue | atopic eczema | Galderma R&D | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03989349 | Jun 2019 → Feb 2022 | atopic eczema | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT03985943 | Jun 2019 → Dec 2021 | atopic eczema | Galderma R&D | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07352566 | Aug 2026 → Jun 2030 expected | atopic eczema, psoriasis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07396168 | Feb 2026 → Jun 2027 expected | lichen planopilaris | The Skin Center Dermatology Group | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04562116 Background | Dec 2021 → Jun 2023 | atopic eczema | Galderma R&D | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nemolizumab | “A Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis (PN)” NCT03181503 ↗23 |
| Known as | CD14152 | “The purpose of this study is to assess the effect of nemolizumab (CD14152) on humoral immune responses to tetanus and meningococcal vaccination in adult and adolescent...” NCT04365387 ↗1“A Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis (PN)” NCT03181503 ↗ |
| Known as | CIM331 | “We wanted to assess the efficacy and safety of nemolizumab (CIM331), a humanized antibody against interleukin-31 receptor A” PMID 28249150 ↗ Mar 2017 |
| Known as | Nemluvio | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297794 ↗ |
| Known as | Nemolizumab-ilto | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297794 ↗ |
| Action | Inhibit | “Nemolizumab, an interleukin (IL)-31 receptor subunit α antagonist, inhibits the IL-31 pathway of itch and skin inflammation in atopic dermatitis.” PMID 39067461 ↗ Jul 2024 |
| Modality | Monoclonal antibody | “Nemolizumab, an anti-IL-31 receptor A mAb” PMID 29753033 ↗ May 2018 |
| Route | Subcutaneous | “receive subcutaneous nemolizumab” PMID 28249150 ↗ Mar 2017 |
| Target | IL31RA | “Nemolizumab, an interleukin (IL)-31 receptor subunit α antagonist, inhibits the IL-31 pathway of itch and skin inflammation in atopic dermatitis.” PMID 39067461 ↗ Jul 2024 |